R&D & Funding

If the UK leaves the EU under the terms of the new Withdrawal Agreement on the 31 January 2020, there will be no change to the current arrangements for EU-related R&D and funding during the Transition Period until 31 December 2020.  

At the end of the Transition Period, depending on the terms of any future relationship agreed with the EU, there are likely to be changes that could affect to business’ R&D activities and funding.

The following is the official guidance previously provided by the Government relating to the life sciences industry, focusing on how to prepare for a no-deal outcome.

 

R&D funding     

The government’s guarantee for EU-funded programmes if there’s no Brexit deal

How Horizon 2020 funding will be affected if there’s a no-deal Brexit

 

Clinical trials   

Please see the Regulation & IP page

 

Data    

Using personal data in your business or organisation if there’s no Brexit deal

 

Animals and biological material   

Importing animals and animal products in a no-deal Brexit

Exporting animals and animal products in a no-deal Brexit

Trading and moving endangered species protected by CITES if there's a no-deal Brexit

Guidance from the HTA on the handling and transport of human tissue and organs if there is a no-deal Brexit

Importing and exporting plants and plant products if there’s a no-deal Brexit

UK regulations on access to genetic resources and the fair and equitable sharing of benefits arising from their utilisation (the Nagoya Protocol) that will continue to be operable after the UK leaves the EU

 

R&D reagents and material              

How to comply with REACH chemical regulations

What operators need to do to move radioactive sources between the UK and EU if there’s a no-deal Brexit